As part of our ongoing aim to bring you reports of significant or innovative developments, we have added a review of a recent study of pharmacovigilance pregnancy data in a large population of patients with chronic inflammatory disease exposed to certolizumab pegol.
This review summarises the analysis of data from 1,392 prospective pregnancies with independent commentary provided by Dr Maninder Mundae, a clinical rheumatologist based in Melbourne.
Please login below to download this issue (PDF)